Point Therapeutics Presents Preclinical Anti-Tumor Data of Talabostat in Combination with Pemetrexed and Erlotinib at AACR-EORTC

Point Therapeutics, Inc. (NASDAQ:POTP) presented
preclinical data on its lead product candidate talabostat,
demonstrating anti-tumor activity when combined with either pemetrexed
or erlotinib in a non-small lung cancer (NSCLC) xenograft model in
immunodeficient mice at a poster session today at the AACR-EORTC-NCI
International Conference on Molecular Targets and Cancer Therapeutics
in Philadelphia, PA.
   As a single agent, talabostat caused a 35% greater reduction in
tumor size than pemetrexed alone. Administration of 500 mg/kg of
pemetrexed alone did not significantly impact tumor growth. When
talabostat and pemetrexed were combined, the anti-tumor effect was
significantly greater (p